Michael Slade

1.4k total citations
54 papers, 670 citations indexed

About

Michael Slade is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Michael Slade has authored 54 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 17 papers in Immunology and 16 papers in Oncology. Recurrent topics in Michael Slade's work include Hematopoietic Stem Cell Transplantation (27 papers), Multiple Myeloma Research and Treatments (15 papers) and T-cell and B-cell Immunology (10 papers). Michael Slade is often cited by papers focused on Hematopoietic Stem Cell Transplantation (27 papers), Multiple Myeloma Research and Treatments (15 papers) and T-cell and B-cell Immunology (10 papers). Michael Slade collaborates with scholars based in United States, United Kingdom and Canada. Michael Slade's co-authors include C.F. Wilkinson, Rizwan Romee, John F. DiPersio, Peter Westervelt, Geoffrey L. Uy, Ravi Vij, Mark A. Schroeder, Scott Goldsmith, Ramzi Abboud and Todd A. Fehniger and has published in prestigious journals such as Science, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael Slade

48 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Slade United States	15	379	212	157	122	90	54	670
Vernon Seow Australia	7	71 0.2×	35 0.2×	173 1.1×	53 0.4×	127 1.4×	7	426
Cara L. Benjamin United States	11	88 0.2×	198 0.9×	94 0.6×	12 0.1×	164 1.8×	25	582
Jansen J. Knez United States	9	48 0.1×	25 0.1×	164 1.0×	30 0.2×	182 2.0×	10	401
F. Melinda Carver United States	12	142 0.4×	26 0.1×	298 1.9×	17 0.1×	104 1.2×	19	566
J. Kömpf Germany	12	66 0.2×	15 0.1×	114 0.7×	8 0.1×	134 1.5×	38	481
Yun Deng China	15	19 0.1×	142 0.7×	148 0.9×	34 0.3×	209 2.3×	50	606
Emin Karaca Türkiye	15	42 0.1×	29 0.1×	109 0.7×	40 0.3×	234 2.6×	66	605
Alejandro Sica United States	7	35 0.1×	121 0.6×	214 1.4×	16 0.1×	166 1.8×	21	462
J.M.C. Wessels Netherlands	12	116 0.3×	76 0.4×	145 0.9×	53 0.4×	202 2.2×	27	497

Countries citing papers authored by Michael Slade

Since Specialization

Citations

This map shows the geographic impact of Michael Slade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Slade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Slade more than expected).

Fields of papers citing papers by Michael Slade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Slade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Slade. The network helps show where Michael Slade may publish in the future.

Co-authorship network of co-authors of Michael Slade

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Slade. A scholar is included among the top collaborators of Michael Slade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Slade. Michael Slade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Slade, Michael, Abir Khaled, Mark A. Fiala, et al.. (2025). Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 25(9). e628–e637.e4.

Slade, Michael, et al.. (2024). Pretransplant desensitization of donor-specific anti-HLA antibodies with plasmapheresis and immunoglobulin produces equivalent outcomes to patients with no donor specific antibodies in haploidentical hematopoietic cell transplant. Leukemia & lymphoma. 65(12). 1811–1819. 2 indexed citations

Warrington, John M., Julie Ritchey, Michael Slade, et al.. (2024). Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors. Cancer Discovery. 14(11). 2109–2121. 5 indexed citations

Shah, Yash, Mark A. Fiala, Keith Stockerl‐Goldstein, et al.. (2024). Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience. Blood. 144(Supplement 1). 3792.1–3792.1.

Goldsmith, Scott, Michael Slade, Mark A. Fiala, et al.. (2024). A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma. Annals of Hematology. 103(11). 4557–4565. 1 indexed citations

Stockerl-Goldstein, Keith, et al.. (2024). Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma. Blood. 144(Supplement 1). 6936–6936.

Gao, Feng, et al.. (2023). Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation. 58(8). 855–862. 14 indexed citations

Crees, Zachary, Michael Slade, Mark A. Schroeder, et al.. (2023). Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Blood. 142(Supplement 1). 2217–2217. 1 indexed citations

Slade, Michael, Mark A. Fiala, Keith Stockerl‐Goldstein, et al.. (2023). A Single Reference Interval for Interpreting Serum Free Light Chains across Patients with Varying Renal Function. Clinical Chemistry. 69(6). 595–605. 3 indexed citations

10.

Fiala, Mark A., Michael Slade, Mark A. Schroeder, et al.. (2023). Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone. Clinical Lymphoma Myeloma & Leukemia. 23(11). 825–828. 1 indexed citations

11.

Slade, Michael, Mark A. Fiala, Zachary Crees, et al.. (2023). Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study. Leukemia Research. 127. 107037–107037. 2 indexed citations

12.

Slade, Michael & Geoffrey L. Uy. (2020). CD123 bi-specific antibodies in development in AML: What do we know so far?. Best Practice & Research Clinical Haematology. 33(4). 101219–101219. 11 indexed citations

13.

Tripathi, Shivani, et al.. (2019). Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study. Journal of the American Academy of Dermatology. 83(6). 1654–1658. 1 indexed citations

14.

Slade, Michael, John F. DiPersio, Peter Westervelt, et al.. (2019). The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation. 26(1). 123–131. 6 indexed citations

15.

Slade, Michael, et al.. (2018). Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 24(10). 2047–2055. 15 indexed citations

16.

Slade, Michael, John F. DiPersio, Peter Westervelt, et al.. (2017). Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation. 23(10). 1736–1743. 36 indexed citations

17.

Goldsmith, Scott, Michael Slade, John F. DiPersio, et al.. (2017). Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplantation. 52(12). 1623–1628. 19 indexed citations

18.

How, Joan, Michael Slade, Khoan Vu, et al.. (2017). T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation. 23(4). 648–653. 30 indexed citations

19.

Rashidi, Armin, Michael Slade, John F. DiPersio, et al.. (2016). Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transplantation. 51(12). 1561–1564. 25 indexed citations

20.

Abboud, Ramzi, Jesse Keller, Michael Slade, et al.. (2016). Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation. 22(10). 1851–1860. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact